US5145852A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaso-active medicament to treat impotence
Assignee: Individual
•
Filing: 1990-07-10
•
Granted: 1992-09-08
•
Expires: 2010-07-10
Abstract
Abstract The invention pertains to the field of vasoactive medicines. The vasoactive medicine, of the type composed of a combination of main active ingredients with papaverine, is characterized by the fact that it comprises at least one alpha blocker and a phosphodiasterase inhibitor representing a total of 5 to 20% by weight of the papaverine. Application to treatment of impotence in men.
Inventors
- 👤 Ronald Virag
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 00:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K31/495; A61K31/505; A61K31/557
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
94 words
A pharmaceutical composition applicable to the treatment of impotence in men, composed of a combination of main active ingredients with papaverine, wherein said main active ingredients comprise an alpha blocker selected from the group consisting of phentolamine, ifenprodil, yohimbine and mixtures thereof; dipyridamol as a phosphodiasterase inhibitor; atropine as an anticholinergic; and piribedil as a dopaminergic, or a prostaglandin selected from the group consisting of PGE 1 and alprostil, or both said piribedil and said prostaglandin, all of said main active ingredients representing a total of 5 to 20% by weight of the papaverine.
Claim 2
Dependent Claim
94 words
A pharmaceutical composition applicable to the treatment of impotence in men, composed of a combination of main active ingredients with papaverine, wherein said main active ingredients comprise an alpha blocker selected from the group consisting of phentolamine, ifenprodil, yohimbine and mixtures thereof; dipyridamol as a phosphodiasterase inhibitor; atropine as an anticholinergic; and piribedil as a dopaminergic, or a prostaglandin selected from the group consisting of PGE 1 and alprostil, or both said piribedil and said prostaglandin, all of said main active ingredients representing a total of 5 to 20% by weight of the papaverine.
Claim 3
Dependent Claim
45 words
A composition according to claim 1, having per 1 ml of injectable solution: papaverine 20 mg; infenprodyl tartrate 0.75 mg as an alpha 1- blocker; yohimbine 0.075 mg as an alpha 2- blocker; atropine 0.025 mg as said anticholinergic; piribedil 0.225 mg as said dopaminergic.
Claim 4
Dependent Claim
50 words
A composition according to claim 1 having per 1 ml of injectable solution: papaverine 20 mg; ifenprodil tartrate 0.75 mg as an alpha 1- blocker; yohimbine 0.075 mg as an alpha 2- blocker; atropine 0.025 mg as anticholinergic; piribedil 0.225 mg as said dopaminergic; alprostil 33 μg as said prostaglandin.
Claim 5
Dependent Claim
36 words
A composition according to claim 1, having per 1 ml of injectable solution: papaverine 20 mg; phentolamine 1 mg as said alpha blocker; dipyridamol 0.25 mg as said phosphodiasterase inhibitor; alprostil 33 μg as said prostaglandin.
Claim 6
Dependent Claim
17 words
A composition according to claim 1, wherein said alpha-blocker is a mixture of ifenprodil tartrate and yohimbine.
Claim 7
Dependent Claim
15 words
A composition according to claim 1, comprising papaverine, dipyridamol atropine, ifenprodil tartrate, yohimbine and piribedil.
Claim 8
Dependent Claim
96 words
In a pharmaceutical composition having a vasoactive effect applicable to the treatment of impotence in men, composed of a combination of main active ingredients with papaverine, the improvement consisting of: an injectable solution having a composition for 1 ml of said solution of papaverine approximately 20 mg; ifenprodil tartrate approximately 0.75 mg as an alpha 1 blocker; atropine approximately 0.025 mg as an anticholinergic; yohimbine approximately 0.075 mg as an alpha 2 blocker; dipyridamol approximately 0.25 mg as a phosphodiasterase inhibitor; piribedil approximately 0.225 mg as a dopaminergic; and alprostil approximately 33 μg as a prostaglandin.
Claim 9
Dependent Claim
96 words
In a pharmaceutical composition having a vasoactive effect applicable to the treatment of impotence in men, composed of a combination of main active ingredients with papaverine, the improvement consisting of: an injectable solution having a composition for 1 ml of said solution of papaverine approximately 20 mg; ifenprodil tartrate approximately 0.75 mg as an alpha 1 blocker; atropine approximately 0.025 mg as an anticholinergic; yohimbine approximately 0.075 mg as an alpha 2 blocker; dipyridamol approximately 0.25 mg as a phosphodiasterase inhibitor; piribedil approximately 0.225 mg as a dopaminergic; and alprostil approximately 33 μg as a prostaglandin.
References Cited (Backward Citations)
US4311707A
Cited
US4801587A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-09-08 | 1996-03-09 | 1996-09-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-09-08 | 2000-03-09 | 2000-09-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-09-08 | 2004-03-09 | 2004-09-08 | $7700.00 | Window Closed / Lapsed |